Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K. Shields, Brian A. Potoski, Ghady Haidar, Binghua Hao, Yohei Doi, Liang Chen, Ellen G. Press, Barry N. Kreiswirth, Cornelius J. Clancy, M. Hong Nguyen

研究成果: Article査読

234 被引用数 (Scopus)

抄録

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

本文言語English
ページ(範囲)1615-1618
ページ数4
ジャーナルClinical Infectious Diseases
63
12
DOI
出版ステータスPublished - 15-12-2016
外部発表はい

All Science Journal Classification (ASJC) codes

  • 微生物学(医療)
  • 感染症

フィンガープリント

「Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル